Cancer drug development: The missing links

Estimation of clinical trial success rates and related parameters

(2018) Chi Heem Wong et al.   BIOSTATISTICS

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment

(2018) Pricivel M. Carrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Therapeutic potential of gambogic acid, a caged xanthone, to target cancer

(2018) Kishore Banik et al.   CANCER LETTERS

Alarming Burden of Triple-Negative Breast Cancer in India

(2018) Krishan K. Thakur et al.   Clinical Breast Cancer

Developmentally inspired human ‘organs on chips’

(2018) Donald E. Ingber   DEVELOPMENT

Direct-to-Consumer Genetic Testing

(2018) Jennifer Gill et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis

(2018) Jean Yoon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A global transcriptional network connecting noncoding mutations to changes in tumor gene expression

(2018) Wei Zhang et al.   NATURE GENETICS

Possible use of Punica granatum (Pomegranate) in cancer therapy

(2018) Amrita Devi Khwairakpam et al.   PHARMACOLOGICAL RESEARCH

Tocotrienols: The promising analogues of vitamin E for cancer therapeutics

(2018) Bethsebie Lalduhsaki Sailo et al.   PHARMACOLOGICAL RESEARCH

Contribution of NIH funding to new drug approvals 2010–2016

(2018) Ekaterina Galkina Cleary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Is genome-guided cancer treatment hyped?

(2018) Jocelyn Kaiser   SCIENCE

Blood test may predict cancer immunotherapy benefit

(2018) Ken Garber   SCIENCE

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study

(2018) Jeffrey Wagner et al.   BMJ-British Medical Journal

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study

(2018) Jeffrey Wagner et al.   BMJ-British Medical Journal

The importance of greater speed in drug development for advanced malignancies

(2018) David J. Stewart et al.   Cancer Medicine

Estimation of The Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

(2018) John Marquart et al.   JAMA Oncology

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

(2018) Vinay Prasad et al.   JAMA Oncology

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies—Reply

(2018) Vinay Prasad et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.

(2018) Juliet Elizabeth Wolford et al.   JOURNAL OF CLINICAL ONCOLOGY

Intra-tumour diversification in colorectal cancer at the single-cell level

(2018) Sophie F. Roerink et al.   NATURE

Early prediction of lenvatinib treatment efficacy by using18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study

(2018) Satoshi Takeuchi et al.   BMJ Open

Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012

(2018) Michael S. Sinha et al.   JAMA Internal Medicine

Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases

(2018) Ajaikumar B. Kunnumakkara et al.   Frontiers in Pharmacology

Designing multi-targeted agents: An emerging anticancer drug discovery paradigm

(2017) Rong-geng Fu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Antiulcer properties of fruits and vegetables: A mechanism based perspective

(2017) Choudhary Harsha et al.   FOOD AND CHEMICAL TOXICOLOGY

An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma

(2017) Larisa Geskin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Spotlight on pomalidomide: could less be more?

(2017) T Zander et al.   LEUKEMIA

The high price of anticancer drugs: origins, implications, barriers, solutions

(2017) Vinay Prasad et al.   Nature Reviews Clinical Oncology

The evidence framework for precision cancer medicine

(2017) Jeffrey A. Moscow et al.   Nature Reviews Clinical Oncology

Functional variomics and network perturbation: connecting genotype to phenotype in cancer

(2017) Song Yi et al.   NATURE REVIEWS GENETICS

International Exchange and American Medicine

(2017) Katrina Armstrong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neem ( Azadirachta indica ): An indian traditional panacea with modern molecular basis

(2017) Subash Chandra Gupta et al.   PHYTOMEDICINE

Butein in health and disease: A comprehensive review

(2017) Ganesan Padmavathi et al.   PHYTOMEDICINE

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

(2017) Jordan Amdahl et al.   PLoS One

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature

(2017) Eric Lu et al.   SEMINARS IN ONCOLOGY

Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for The Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Metastatic Breast Cancer from A US Private Third-Party Payer Perspective

(2017) G Suri et al.   VALUE IN HEALTH

Accumulated Treatment Cost of New Therapies in Multiple Myeloma: Comparing the Combination of Daratumumab, Bortezomib and Dexamethasone with Carfilzomib and Dexamethasone For WHO Have Received at Least One Prior Therapy in Brazil

(2017) C Del Rey et al.   VALUE IN HEALTH

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

(2017) Austin Lammers et al.   Blood Cancer Journal

Do cancer drugs improve survival or quality of life?

(2017) Vinay Prasad   BMJ-British Medical Journal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Do cancer drugs improve survival or quality of life?

(2017) Vinay Prasad   BMJ-British Medical Journal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints

(2017) Tracy Rupp et al.   JAMA Internal Medicine

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

(2017) Vinay Prasad et al.   JAMA Internal Medicine

Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database

(2017) Patrick Tilleul et al.   JOURNAL OF MEDICAL ECONOMICS

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

(2017) Sonali M Smith et al.   Lancet Haematology

Taking Care of Our Friends and Neighbors

(2017) Tomasz M. Beer et al.   JAMA Oncology

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

(2017) Sham Mailankody et al.   JAMA Oncology

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

(2017) Sebastian Salas-Vega et al.   JAMA Oncology

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France

(2016) Aline Hurtaud et al.   BREAST

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases

(2016) Ajaikumar B Kunnumakkara et al.   BRITISH JOURNAL OF PHARMACOLOGY

The fractions of cancer attributable to modifiable factors: A global review

(2016) David C. Whiteman et al.   Cancer Epidemiology

The potential role of boswellic acids in cancer prevention and treatment

(2016) Nand Kishor Roy et al.   CANCER LETTERS

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer

(2016) Javadi Monisha et al.   CURRENT DRUG TARGETS

NF-?B Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization

(2016) Javadi Monisha et al.   CURRENT PHARMACEUTICAL DESIGN

Blood-Based Screening for Colon Cancer

(2016) Ravi B. Parikh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices

(2016) Sham Mailankody et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Price, value, and the cost of cancer drugs

(2016) Tito Fojo et al.   LANCET ONCOLOGY

Precision oncology: origins, optimism, and potential

(2016) Vinay Prasad et al.   LANCET ONCOLOGY

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

(2016) Chul Kim et al.   MAYO CLINIC PROCEEDINGS

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer

(2016) Daniel A. Goldstein et al.   MEDICAL ONCOLOGY

Who Is in the Driver’s Seat: Tracing Cancer Genes Using CRISPR-Barcoding

(2016) Jarno Drost et al.   MOLECULAR CELL

Perspective: The precision-oncology illusion

(2016) Vinay Prasad   NATURE

Putting a price on cancer

(2016) Richard Sullivan et al.   Nature Reviews Clinical Oncology

Role of non-coding sequence variants in cancer

(2016) Ekta Khurana et al.   NATURE REVIEWS GENETICS

Wnt signaling in cancer

(2016) T Zhan et al.   ONCOGENE

BEZ235: When Promising Science Meets Clinical Reality

(2016) G. Pongas et al.   ONCOLOGIST

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies

(2016) S. Mailankody et al.   ONCOLOGIST

Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far

(2016) Devivasha Bordoloi et al.   Recent Patents on Anti-Cancer Drug Discovery

Serendipity in Cancer Drug Discovery: Rational or Coincidence?

(2016) Sahdeo Prasad et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Analysis of Costs Associated With Administration of Intravenous Single-Drug Therapies in Metastatic Breast Cancer in a U.S. Population

(2016) Gregory B. Kruse et al.   JOURNAL OF MANAGED CARE PHARMACY

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

(2015) V. Prasad et al.   BLOOD

Multiplying therapies and reducing toxicity in metastatic melanoma

(2015) Paul R Massey et al.   CANCER BIOLOGY & THERAPY

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

(2015) Chi-Ping Day et al.   CELL

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

(2015) A. Eaton et al.   CLINICAL CANCER RESEARCH

Medical Debates and Medical Reversal

(2015) Adam S. Cifu et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Non-inferiority trials: why oncologists must remain wary

(2015) Mauricio Burotto et al.   LANCET ONCOLOGY

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

The re-emergence of natural products for drug discovery in the genomics era

(2015) Alan L. Harvey et al.   NATURE REVIEWS DRUG DISCOVERY

Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients

(2015) Jeffrey R. Scott et al.   PEDIATRIC BLOOD & CANCER

Potential of butein, a tetrahydroxychalcone to obliterate cancer

(2015) Ganesan Padmavathi et al.   PHYTOMEDICINE

Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT

(2015) Karin Berger et al.   SUPPORTIVE CARE IN CANCER

The Strength of Association Between Surrogate End Points and Survival in Oncology

(2015) Vinay Prasad et al.   JAMA Internal Medicine

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

(2015) Chul Kim et al.   JAMA Internal Medicine

Colorectal Cancer Survival Gains and Novel Treatment Regimens

(2015) Irfan Jawed et al.   JAMA Oncology

Five Years of Cancer Drug Approvals

(2015) Sham Mailankody et al.   JAMA Oncology

Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels

(2015) Tait D. Shanafelt et al.   Journal of Oncology Practice

Cost-Effectiveness Analysis of Granisetron-Based versus Standard Antiemetic Regimens in Low-Emetogenic Chemotherapy: A Hospital-based Perspective from Malaysia

(2014) Chan Huan Keat et al.   Asian Pacific Journal of Cancer Prevention

Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma

(2014) A.H.M.M. Arits et al.   BRITISH JOURNAL OF DERMATOLOGY

Multi-targeted therapy of cancer by niclosamide: A new application for an old drug

(2014) Yonghe Li et al.   CANCER LETTERS

Cancer Cell Lines for Drug Discovery and Development

(2014) J. L. Wilding et al.   CANCER RESEARCH

Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

(2014) C.L. Attard et al.   Current Oncology

Modern Drug Development

(2014) Muthiah Vaduganathan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Accelerated Approval of Oncologic Drugs

(2014) Vinay Prasad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care

(2014) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients

(2014) Vinay Prasad et al.   JOURNAL OF CLINICAL ONCOLOGY

Translational research in oncology—10 years of progress and future prospects

(2014) James H. Doroshow et al.   Nature Reviews Clinical Oncology

Implementing personalized cancer care

(2014) Richard L. Schilsky   Nature Reviews Clinical Oncology

National Cancer Institute awards—a work in progress

(2014) Tito Fojo et al.   Nature Reviews Clinical Oncology

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

(2014) Patti Curl et al.   PLoS One

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

(2014) Tito Fojo et al.   JAMA Otolaryngology-Head & Neck Surgery

Reevaluating the Accelerated Approval Process for Oncology Drugs

(2013) W. H. Wilson et al.   CLINICAL CANCER RESEARCH

How can attrition rates be reduced in cancer drug discovery?

(2013) Lucas Moreno et al.   Expert Opinion on Drug Discovery

Cancer Drugs in the United States: Justum Pretium—The Just Price

(2013) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging patterns of somatic mutations in cancer

(2013) Ian R. Watson et al.   NATURE REVIEWS GENETICS

The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

(2013) L. P. Garrison et al.   ONCOLOGIST

Total cost comparison in relapsed/refractory multiple myeloma

(2013) Brian Durie et al.   JOURNAL OF MEDICAL ECONOMICS

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer

(2013) Emilia Kansanen et al.   Redox Biology

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

(2012) L. R. Molife et al.   ANNALS OF ONCOLOGY

Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy

(2012) A Ogden et al.   CELL DEATH AND DIFFERENTIATION

Regorafenib for cancer

(2012) Dirk Strumberg et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Why Do Phase III Clinical Trials in Oncology Fail so Often?

(2012) L. Amiri-Kordestani et al.   JNCI-Journal of the National Cancer Institute

Hazard ratios in cancer clinical trials—a primer

(2012) Krastan B. Blagoev et al.   Nature Reviews Clinical Oncology

The Valley of Death in anticancer drug development: a reassessment

(2012) David J. Adams   TRENDS IN PHARMACOLOGICAL SCIENCES

Delivering affordable cancer care in high-income countries

(2011) Richard Sullivan et al.   LANCET ONCOLOGY

NF- B in Cancer: A Matter of Life and Death

(2011) B. B. Aggarwal et al.   Cancer Discovery

Mouse models for cancer research

(2011) Wei Zhang et al.   Chinese Journal of Cancer

Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival

(2010) Julia Wilkerson et al.   CANCER JOURNAL

 -Tocotrienol Inhibits Pancreatic Tumors and Sensitizes Them to Gemcitabine Treatment by Modulating the Inflammatory Microenvironment

(2010) A. B. Kunnumakkara et al.   CANCER RESEARCH

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

(2010) T. Fojo et al.   CLINICAL CANCER RESEARCH

Cancer Prevention With Natural Compounds

(2010) Norleena P. Gullett et al.   SEMINARS IN ONCOLOGY

Models for prevention and treatment of cancer: Problems vs promises

(2009) Bharat B. Aggarwal et al.   BIOCHEMICAL PHARMACOLOGY

Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics

(2009) Fazlul H. Sarkar et al.   CANCER TREATMENT REVIEWS

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Multitargeted therapy of cancer by silymarin

(2008) Kumaraguruparan Ramasamy et al.   CANCER LETTERS

Natural products in drug discovery

(2008) A HARVEY   DRUG DISCOVERY TODAY

Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better

(2008) T. Fojo   ONCOLOGIST

Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data

(2008) W. D. Stein et al.   ONCOLOGIST

Cancer is a Preventable Disease that Requires Major Lifestyle Changes

(2008) Preetha Anand et al.   PHARMACEUTICAL RESEARCH